Detalhe da pesquisa
1.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272512
2.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood
; 143(20): 2029-2036, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394666
3.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Blood
; 143(13): 1242-1258, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096363
4.
Quad-class exposed/refractory myeloma is associated with short survival.
Br J Haematol
; 204(1): 186-190, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37833834
5.
T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Blood
; 139(26): 3681-3687, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404996
6.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
7.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
8.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Eur J Haematol
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712850
9.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Am J Hematol
; 99(3): 350-359, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165016
10.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
11.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood
; 138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827114
12.
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Blood
; 138(25): 2686-2695, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479366
13.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica
; 108(10): 2774-2782, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078253
14.
Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.
Eur Radiol
; 33(9): 6438-6447, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37022439
15.
Clinical features and outcomes of patients admitted to the ICU for Cyclophosphamide-associated cardiac toxicity: a retrospective cohort.
Support Care Cancer
; 31(8): 474, 2023 Jul 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37462731
16.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Br J Haematol
; 198(6): 988-993, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608261
17.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671975
18.
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Br J Haematol
; 197(1): 82-96, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35166376
19.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood
; 135(18): 1531-1540, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108228
20.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931